Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

GlioZERO Advanced technologies for zeroing in on high-grade gliomas

Coordinator
Fondazione Istituto Italiano Di Tecnologia, Italy
Runs
1 March 2026 to 28 February 2030
Status
Running
EU funding
€792k
Total cost
—
Partners
11 organisations in 5 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101236541

What the project is doing

In the project's own words, from its summary on CORDIS.

Despite advances in diagnosis and therapy, glioblastoma (GBM) remains one of the most challenging cancers to treat, with overall survival under two years and a five-year survival rate of just 5%. This poor prognosis stems from three key factors: anatomical barriers, biological heterogeneity, immunosuppressive tumor microenvironment (TME). GlioZERO will establish a network of scientists with expertise in drug delivery, immunology, neurosurgery, robotics, and computational sciences to design microstructured polymeric films (microGRID) enabling deep, uniform, and sustained release of various therapeutic agents at the tumor margins; assess the efficacy of multimodal therapies in rigorous GBM models, leveraging microGRID to overcome anatomical barriers and systemic toxicity; improve surgical resection through intraoperative AI-assisted imaging; and employ advanced biological mapping to identify post-surgical TME alterations driving recurrence.

To achieve these objectives, GlioZERO will bring together two EU Research Institutions, specialized in drug delivery, robotics, imaging (IIT) and brain cancer biology (Curie); two EU Enterprises, with expertise in neurosurgery (HUM) and computational modeling (BioIRC); four world-renowned US institutions advancing various therapies against GBM, including targeted therapies and immunotherapies (Stanford), oncolytic viruses (MD Anderson), anti-epileptic therapies (UCSF), and image-guided surgical therapies (BWH); and a Japanese partner (KU), focused on nano-therapies.

Through interdisciplinary, intersectoral, and international secondments, GlioZERO will train a new generation of EU scientists, develop a novel class of drug delivery systems, and identify more effective therapies against GBM. Finally, partnerships with biotech accelerators in Silicon Valley, the Texas Medical Center, and the Greater Boston area will instill an entrepreneurial mindset and accelerate the clinical translation of GlioZERO discoveries and technologies.

Topics

Who is involved

OrganisationCityCountryRole
Fondazione Istituto Italiano Di TecnologiaGenovaItalyCoordinator
Institut CurieParisFranceParticipant
Humanitas Mirasole SpARozzano (Mi)ItalyParticipant
Scuola Superiore Di Studi Universitari E Di Perfezionamento S AnnaPisaItalyAssociatedpartner
Universita HumanitasPieve EmanueleItalyAssociatedpartner
National University Corporation Kanazawa UniversityKanazawaJapanAssociatedpartner
Istrazivacko Razvojni Centar Za Bioinzenjering Bioirc DooKragujevacSerbiaParticipant
Board of Trustees of the Leland Stanford Junior UniversityStanfordUnited StatesAssociatedpartner
Brigham IncBostonUnited StatesAssociatedpartner
The Regents of the University of CaliforniaOaklandUnited StatesAssociatedpartner
The University of Texas MD Anderson Cancer CenterHoustonUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI